Monoamines, BDNF, IL-6 and Corticosterone in CSF in Patients with Parkinson's Disease and Major Depression

Overview

Journal J Neurol

Specialty Neurology

Date 2009 Oct 22

PMID 19844754

Citations 29

Authors

Sven Palhagen

Hongshi Qi

Bjorn Martensson

Jan Walinder

Ann-Kathrine Granerus

Per Svenningsson

Affiliations

Soon will be listed here.

Abstract

The biochemical basis of major depression (MD) in Parkinson's disease (PD) is largely unknown. To increase our understanding of MD in PD patients, the levels of monoamine metabolites (HVA, 5-HIAA and MHPG), BDNF, orexin-A, IL-6 and corticosterone were examined in cerebrospinal fluid. The analyses were performed in MD patients with (n = 11) and without (n = 12) PD at baseline and after 12 weeks' of treatment with the antidepressant citalopram, and in patients with solely PD (n = 14) at baseline and after 12 weeks. The major findings were that PD patients with MD had significantly lower baseline levels of MHPG, corticosterone and IL-6 when compared to patients with solely MD. In response to citalopram treatment, patients with solely MD exhibited an expected decrease in 5-HIAA and MHPG levels which was not found in PD patients with MD. Moreover, the levels of BDNF and IL-6 were lower in PD patients with MD compared with patients with solely MD after treatment with citalopram. Thus, the biochemical basis and the response to citalopram differ between PD patients with MD and patients with solely MD.

Citing Articles

Associations Between Neuropsychiatric Symptoms and Inflammation in Neurodegenerative Dementia: A Systematic Review.

Swann P, Mirza-Davies A, OBrien J J Inflamm Res. 2024; 17:6113-6141.

PMID: 39262651 PMC: 11389708. DOI: 10.2147/JIR.S385825.

Genetic Insights into the Molecular Pathophysiology of Depression in Parkinson's Disease.

Angelopoulou E, Bougea A, Paudel Y, Georgakopoulou V, Papageorgiou S, Piperi C Medicina (Kaunas). 2023; 59(6).

PMID: 37374342 PMC: 10301401. DOI: 10.3390/medicina59061138.

Active constituents of saffron ( L.) and their prospects in treating neurodegenerative diseases (Review).

Yang W, Qiu X, Wu Q, Chang F, Zhou T, Zhou M Exp Ther Med. 2023; 25(5):235.

PMID: 37114174 PMC: 10127217. DOI: 10.3892/etm.2023.11934.

Cerebrospinal fluid cytokines in geriatric patients with depressive disorders: A retrospective case-control study.

Schou M, Larsen J, Stunes A, Saether S Front Psychiatry. 2022; 13:947605.

PMID: 36172507 PMC: 9510363. DOI: 10.3389/fpsyt.2022.947605.

Inflammatory markers and depression in Parkinson's disease: a systematic review.

Ramanzini L, Camargo L, Silveira J, Bochi G Neurol Sci. 2022; 43(12):6707-6717.

PMID: 36040559 DOI: 10.1007/s10072-022-06363-7.

References

Willner P . The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol. 1997; 12 Suppl 3:S7-14. DOI: 10.1097/00004850-199707003-00002. View

Pineyro G, Blier P . Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev. 1999; 51(3):533-91. View

Belmaker R, Agam G . Major depressive disorder. N Engl J Med. 2008; 358(1):55-68. DOI: 10.1056/NEJMra073096. View

Seckl J, Campbell J, Edwards C, CHRISTIE J, Whalley L, Goodwin G . Diurnal variation of plasma corticosterone in depression. Psychoneuroendocrinology. 1990; 15(5-6):485-8. DOI: 10.1016/0306-4530(90)90071-g. View

Shoulson I, Glaubiger G, Chase T . On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 1975; 25(12):1144-8. DOI: 10.1212/wnl.25.12.1144. View

Wahlberg K, Ghatan P, Modell S, Nygren A, Ingvar M, Asberg M . Suppressed neuroendocrine stress response in depressed women on job-stress-related long-term sick leave: a stable marker potentially suggestive of preexisting vulnerability. Biol Psychiatry. 2008; 65(9):742-7. PMC: 2745651. DOI: 10.1016/j.biopsych.2008.10.035. View

Leentjens A . Depression in Parkinson's disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol. 2004; 17(3):120-6. DOI: 10.1177/0891988704267456. View

Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View

Palhagen S, Carlsson M, Curman E, Walinder J, Granerus A . Depressive illness in Parkinson's disease--indication of a more advanced and widespread neurodegenerative process?. Acta Neurol Scand. 2008; 117(5):295-304. DOI: 10.1111/j.1600-0404.2007.00986.x. View

10.

Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K . CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2006; 250(1-2):120-3. DOI: 10.1016/j.jns.2006.08.004. View

11.

Zhang J, Sokal I, Peskind E, Quinn J, Jankovic J, Kenney C . CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008; 129(4):526-9. PMC: 2688655. DOI: 10.1309/W01Y0B808EMEH12L. View

12.

Cryan J, OLeary O, Jin S, Friedland J, Ouyang M, Hirsch B . Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc Natl Acad Sci U S A. 2004; 101(21):8186-91. PMC: 419578. DOI: 10.1073/pnas.0401080101. View

13.

Salehi Z, Mashayekhi F . Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease. J Clin Neurosci. 2008; 16(1):90-3. DOI: 10.1016/j.jocn.2008.03.010. View

14.

Kish S, Tong J, Hornykiewicz O, Rajput A, Chang L, Guttman M . Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain. 2007; 131(Pt 1):120-31. DOI: 10.1093/brain/awm239. View

15.

Menza M, Dobkin R, Marin H, Mark M, Gara M, Buyske S . A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2008; 72(10):886-92. PMC: 2677475. DOI: 10.1212/01.wnl.0000336340.89821.b3. View

16.

Mayeux R, Stern Y, Cote L, Williams J . Altered serotonin metabolism in depressed patients with parkinson's disease. Neurology. 1984; 34(5):642-6. DOI: 10.1212/wnl.34.5.642. View

17.

Blennow K, Wallin A, Gottfries C, Karlsson I, Mansson J, Skoog I . Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18-88 years of age. Eur Neuropsychopharmacol. 1993; 3(1):55-61. DOI: 10.1016/0924-977x(93)90295-w. View

18.

Wilcox C, Aminoff M, Millar J, Keenan J, Kremer M . Circulating levels of corticotrophin and cortisol after infusions of L-DOPA, dopamine and noradrenaline, in man. Clin Endocrinol (Oxf). 1975; 4(2):191-8. DOI: 10.1111/j.1365-2265.1975.tb01526.x. View

19.

Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K . Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004; 318(1):121-34. DOI: 10.1007/s00441-004-0956-9. View

20.

Nestler E, Carlezon Jr W . The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006; 59(12):1151-9. DOI: 10.1016/j.biopsych.2005.09.018. View